Magenta Therapeutics, Inc. approved a restructuring plan (the “Plan”) to reduce the Company's operations to preserve financial resources, resulting in a reduction of the Company's workforce by up to 56 positions, or approximately 84%, to be substantially completed by February 17, 2023. In connection with the Plan, Jason Gardner, Chief Executive Officer will be leaving the Company to pursue new opportunities.